R&G PharmaStudies Co

R&G PharmaStudies Co EBITDA per Share

The EBITDA per Share of R&G PharmaStudies Co (301333.SZ) as of Oct 21, 2026 is 1.40 CNY. In the previous year, EBITDA per Share was 1.38 CNY — a change of 1.40% (higher).

EBITDA per Share

1.40CNY

YoY

1.40%

Last updated:

EBITDA per Share of R&G PharmaStudies Co is 2025 1.40 CNY. EBITDA per Share of R&G PharmaStudies Co was 2024 1.38 CNY. It decreases by 1.40% higher compared to the previous year.

The R&G PharmaStudies Co EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2019
1.05 CNY
Jan 1, 2020
1.09 CNY
Jan 1, 2021
1.28 CNY
Jan 1, 2022
1.92 CNY
Jan 1, 2023
1.58 CNY
Jan 1, 2024
1.38 CNY
Jan 1, 2025
1.40 CNY
The R&G PharmaStudies Co EBITDA per Share history
YEAREBITDA per ShareYoY
1.40CNY+1.40%
1.38CNY-12.68%
1.58CNY-17.93%
1.92CNY+50.58%
1.28CNY+17.62%
1.09CNY+3.43%
1.05CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

R&G PharmaStudies Co Stock analysis

What does R&G PharmaStudies Co do? R&G PharmaStudies Co Ltd, based in Beijing, China, provides clinical trial outsourcing services within the Health Care sector. The company offers a range of services including clinical trial operations, site management, biological sample testing, data management, statistical analysis, consulting, and clinical pharmacology. With 1,926 employees, it operates primarily in the domestic Chinese market and was listed on the stock market on 2 August 2022. R&G PharmaStudies Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about R&G PharmaStudies Co stock

EBITDA per Share of R&G PharmaStudies Co is 1.40 CNY in 2025.

EBITDA per Share of R&G PharmaStudies Co changed from 1.38 CNY to 1.40 CNY, representing a 1.40% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share R&G PharmaStudies Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — R&G PharmaStudies Co

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — R&G PharmaStudies Co